Serologic biomarker for coronary heart disease (CHD) detection, and application thereof

A biomarker, coronary heart disease technology, applied in the fields of clinical medicine, biotechnology and biochemistry, laboratory medicine, can solve the problem of low accuracy and achieve the effect of accurate prediction

Inactive Publication Date: 2015-01-28
雷桅
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this method is judged by the concentration of peroxidase, and the accuracy is not high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serologic biomarker for coronary heart disease (CHD) detection, and application thereof
  • Serologic biomarker for coronary heart disease (CHD) detection, and application thereof
  • Serologic biomarker for coronary heart disease (CHD) detection, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Subject group

[0021] The research protocol used in the present invention has also been approved by the hospital ethics committee, and the informed consent of the patients participating in the test was obtained in 2013.

[0022] The clinical samples of this experiment included 279 cases of coronary heart disease group and 268 cases of control group. The coronary heart disease group was divided into three subgroups: acute myocardial infarction (AMI), stable angina pectoris group (SAP) and unstable angina pectoris group (UAP). The samples were obtained from the Department of Cardiology and the Physical Examination Center of the Affiliated Hospital of Guangdong Medical College. The two groups were matched on age and sex.

[0023] Inclusion criteria for the coronary heart disease group: (just meet one of the following conditions)

[0024] (1) History of previous stent implantation (PCI) or coronary artery bypass grafting (CABG);

[0025] (2) Coronary angiography (CAG) c...

Embodiment 2

[0036] Physiological index test and blood collection

[0037] All participants underwent a standard clinical examination prior to sampling. Registration information and detection indicators include: gender, age, body mass index (BMI), smoking, hypertension, diabetes mellitus (DM), atrial fibrillation (AF), stroke, high total cholesterol (High TC), high triglycerides (High TG), low-high-density lipoprotein cholesterol (Low HDL), high-low-density lipoprotein cholesterol (High LDL), lipoprotein (Lp(a)), blood urea nitrogen (BUN), serum creatinine (Scr), serum Uric acid (SUA), glucose (Glu), total cholesterol (CHOL), triglyceride (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), apolipoprotein A1 (ApoA1), Lipoprotein B (ApoB), where BMI = weight / height2. Smokers were defined as having a smoking history of at least one year to date. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or those who were taking antihypertensive...

Embodiment 3

[0046] Determination of Samd3 content level

[0047] The determination method of serum Samd3 content is as follows:

[0048]The collected peripheral blood serum was tested by ELISA, including 279 cases in the coronary heart disease group and 268 cases in the control group. All blood samples were collected within 24 hours after the patient's physical examination, with a collection volume of 3-5 ml, and the serum was centrifuged within 24 hours after collection. The separation conditions were 3000 bpm, 10 min, and 4 °C. Then detect the content of Samd3 according to the ELISA method, the detailed experimental steps are as follows:

[0049] (1) Dilution and sample addition of the standard: set 15 wells of the standard on the target antibody-coated microtiter plate, add 100 μl of the standard to the 1st, 2nd, and 3rd wells respectively, and then add 100 μl of the standard to the 1st, Add 50 μl of standard diluent to the 2nd and 3rd wells, and mix well; then add 100 μl from the 1s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the fields of laboratory medicine, clinical medicine, biotechnology and biochemistry, and relates to a serologic biomarker for coronary heart disease (CHD) detection, and application thereof. The biomarker is human SAMD3 (sterile alpha motif domain-containing protein 3). The biomarker is closely related to CHD incidence and development; SAMD3 is used as the biomarker for CHD incidence prediction and CHD development degree judgment, so that compared with the conventional pathological type diagnosis of CHD incidence and prognosis, the biomarker can more individually and accurately predict the early incidence situation and grade malignancy of CHD; moreover, the marker can be used for preparing a kit for screening CHD or assisting in pathological identification, clinical diagnosis and subtype discrimination of CHD.

Description

technical field [0001] The invention relates to a serological biomarker for detecting coronary heart disease and its application, in particular to a biomarker for coronary heart disease—serum Samd3 protein and its application in coronary heart disease screening and clinical diagnosis, belonging to laboratory medicine , clinical medicine, biotechnology and biochemistry. Background technique [0002] In recent years, with the improvement of people's living standards, the proportion of population aging has been increasing. Globally, the incidence of cardiovascular diseases such as hypertension, coronary heart disease, diabetes, and pulmonary hypertension has shown a significant upward trend, which has become a serious threat to human health. one of the main diseases. According to the latest statistics from the World Health Organization, about 17.3 million people die from various cardiovascular and cerebrovascular diseases every year in the world, accounting for about 30% of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47G01N33/68
CPCC07K14/47G01N33/68
Inventor 雷桅陈灿税晓容
Owner 雷桅
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap